GLOBE LIFE INC. (GL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $172.79, GLOBE LIFE INC. (GL) is priced for 14.6% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-26.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/GL

Headline

FieldValue
TickerGL
CompanyGLOBE LIFE INC.
Sector / IndustryFinancial Services
Current price$172.79/sh
CompositionLife insurance 55% / Health insurance 25% / Investment 20%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed14.6%
Return on equity now19.4%
ROE gap-4.8pp
Price-to-book2.16x

Solve inputs: computed at a 8.9% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026).

How unusual the bet is: within-range

ReferenceValue
vs own history-0.33σ
cohort percentile (of 78 peers)63
sustained it ~10 years at this level61%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.01x3expensive
Earnings1.06x1expensive
Relative0
Growth0

Families that justify the price: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.8%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
Bank Fair Value (P/TBV)$236.910.73xyesTBVPS $73.72 × 3.21x (ROE (TTM) 19.7% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.12% allowance/loans → ×0.93)
Relative ValuationRelativenoP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$170.531.01xyesBV/sh $80.10, ROE (TTM) 19.7%, ke 9.3%
Two-Stage Excess ReturnAsset$246.130.70xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowthnoRev $6.2B, growth 5% (input: historical growth; tapered), Terminal P/S: 1.8x / 2.1x / 2.5x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelativenoEPS $15.05, growth 20% (input: historical EPS growth), PEG=0.55 (Undervalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$164.701.05xyes√(22.5 × EPS $15.05 × BVPS $80.10) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsnoEPS $15.05 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAssetno
P/Sales SectorRelativeno
PEG Fair ValueRelativenoEPS $15.05 × (PEG 1.5 × growth 19.8% (input: historical EPS growth)) → PE 29.7x
Earnings YieldEarnings$162.701.06xyesEPS $15.05 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Life insurancefinancialequity$3.3bwithheldunresolved standalone equity facts required
Health insurancefinancialequity$1.5bwithheldunresolved standalone equity facts required
Investmentfinancialequity$1.2bwithheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (buyback)-5.5%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Start with the share count, because it is doing more work here than the business is.

Weighted average diluted shares fell to 78.9 million in the second quarter of 2026 from 82.8 million a year earlier, after the company bought back 1.1 million shares for 175 million dollars in the quarter alone. Over the last four years the count has come down about 5.6 percent a year. That is not a one-off return of capital; it is the operating model. Globe Life's 10-K describes the mechanism without embellishment, noting that per-share results move differently from the underlying figures because the number of diluted shares outstanding generally decreases from year to year as a result of our share repurchase program, and that Management generally determines the amount of repurchases based on the amount of excess cash flows and other available sources. In November 2024 the board authorised up to 1.8 billion dollars under the existing programme.

Now the part that makes the buyback sustainable rather than clever. The underlying business is boring in the specific way insurance underwriters want to be boring. Life insurance produced an underwriting margin of 42 percent of premium in the second quarter, up from 41 percent, and the ratio of administrative expense to premium was 7.0 percent against 7.1 percent a year earlier. Total premium grew 7 percent. Those are not numbers that swing with credit cycles or catastrophe seasons, which is exactly why the company can commit to returning roughly 83 percent of earnings without needing to guess about next year's losses.

The products are the reason, and the structure of the accounts shows it. Globe Life sells small-face-amount life policies and limited-benefit supplemental health cover to working households, largely through captive agency divisions rather than brokers. Its own 10-K defines the metric that matters as one that essentially represents gross profit margin on insurance products before insurance administrative expenses and consists primarily of premium less net policy benefits, acquisition expenses, and commissions, and it deliberately keeps investment results out of that measure: Required interest on policy liabilities is reflected as a component of the Investment segment (rather than as a component of underwriting margin. The second-quarter split makes the consequence concrete. Insurance underwriting income contributed 4.69 dollars a share; excess investment income contributed 0.49. Roughly nine tenths of the earnings engine is mortality and expense, not investment spread. When rates move, most of this business does not.

The largest channel is holding. American Income produced 466.3 million dollars of the quarter's 860.8 million dollars of life premium at an underwriting margin of 46 percent of premium, unchanged on the year. A distribution arm that reaches working households through affinity and workplace relationships is not something a competitor assembles quickly, and the margin says the relationship has not been competed away.

The recruiting engine is showing signs of life in the channels that were struggling. Average producing agent count rose 8 percent at Liberty National and 7 percent at Family Heritage over the year-ago quarter, and both divisions grew underwriting margin 10 percent. Agent count is the input that eventually becomes premium, and it moves first.

Against the peer set, the profitability is genuinely top of the group. Globe Life keeps roughly nineteen cents of every revenue dollar as profit, which puts it alongside PRI at 23.0 percent and AFL at 25.6 percent and well clear of MET at 4.7 percent, PRU at 5.5 percent and UNM at 5.9 percent. Those larger names carry annuity and institutional books whose returns depend on investment spread and reserve assumptions across long horizons. Globe Life's business is smaller, simpler and considerably more profitable per dollar of revenue, and management raised full-year guidance in July rather than reaffirming it.

Bear Case

Premium is a lagging number and sales is a leading one, and at Globe Life the two are pointing in different directions. Total premium grew 7 percent in the second quarter of 2026. Total life net sales fell 3 percent. Inside that, the direct-to-consumer channel dropped 15 percent and American Income, the largest agency division, slipped 2 percent. Net sales is annualised premium on newly issued policies. Today's sales are the premium base three and five years from now, so a sales line that goes backwards while premium still rises is the shape of a business a little past the top of its own cycle rather than one accelerating into a new one.

The mix underneath is moving toward the thinner product. Health premium rose 16 percent in the quarter while life premium rose 3 percent, and the United American division, which sells Medicare Supplement through independent agents, grew health premium 29 percent. But health underwriting margin came in at 23 percent of premium against 26 percent a year earlier, while life held 42 percent. The growth is arriving in the segment that keeps less of each premium dollar. Medicare Supplement is priced against medical trend and repriced annually by regulators; it is a volume business, not a margin business, and the 10-K describes exactly that discipline, noting that rate filings are made and the new premium rates generally become effective in the following year on new business issued.

The distribution model carries a risk that most insurers do not. Globe Life's premium comes overwhelmingly from agents it recruits, trains and pays on commission, and its own 10-K is direct about the exposure: We employ controls and procedures designed to prevent and detect agent misconduct; however, such controls and procedures cannot be 100% effective in all cases, and such instances could result in adverse findings in either examinations or litigation. The same filing lists regulatory authorities' power to conduct investigations, and to bring administrative or judicial proceedings against us. Legal proceedings have been a recurring line in the reconciliation between operating and reported earnings, and shareholder derivative litigation remains active. None of that is fatal. It is a standing tax on a distribution model that is otherwise the company's best asset.

The price says the market is comfortable with all of it. Globe Life changes hands for about 2.2 times its book value, which sits in the upper half of the range its peer group trades at, and that multiple requires the company to sustain a return on equity near 15.2 percent indefinitely. On a trailing basis it earns about 19.4 percent, so there is headroom. The catch is in the second decimal place of the balance sheet rather than in the earnings. Book value per share of 78.18 dollars at June 30, 2026 was 18 percent higher than a year earlier, but book value per share excluding accumulated other comprehensive income was 100.04 dollars and rose 11 percent. The difference is unrealised movement on the bond portfolio. Much of the reported book value growth is a rate effect that reverses if rates back up, and the denominator of the return the price depends on moves with it.

Read the return the way management reports it and the margin of comfort narrows considerably. Net income as a return on equity was 18.4 percent for the six months to June 2026, against 18.8 percent in the same period of 2025. Net operating income as a return on equity excluding that comprehensive income adjustment was 14.3 percent, against 14.4 percent. On that basis the company is not comfortably above what the price requires; it is sitting on it, and slipping fractionally. Roughly 60 percent of firms earning a return like this held it a decade. That is better than a coin toss and a long way from a certainty.

Finally, the buyback that carries the per-share story is not free. Returning roughly 83 percent of earnings means retaining about a sixth of them, and a business that retains a sixth of its earnings can only grow book value as fast as that retention plus the return it earns on it. The share count can keep falling. The equity base underneath each remaining share grows slowly. If sales keep declining, the repurchase becomes the whole growth story, and repurchases at more than two times book value are a use of capital that requires the return to persist to make sense.

Valuation

An insurer is worth the return it earns on the capital it holds, so the useful question is not what multiple of earnings the shares carry but what return the market is assuming. Globe Life trades near 2.2 times its book value. Invert that and the answer is a return on equity of roughly 15.2 percent, sustained. The company has recently been earning about 19.4 percent on a trailing basis. The price is therefore asking for less than the business has been delivering, which is an unusual place to start.

The gap is real but it is not as wide as those two figures make it look, because everything depends on which book value you use. On the reported basis, book value per share reached 78.18 dollars at the end of June 2026, up 18 percent in a year, and net income as a return on equity ran 18.4 percent for the first six months. On the basis management prefers, which strips out unrealised movements in the bond portfolio, book value per share was 100.04 dollars and net operating income as a return on that equity was 14.3 percent. Two honest numbers, one business. The first flatters the return by shrinking the denominator; the second does not. The requirement embedded in the market's assumption sits between them, and closer to the second.

The methods are unusually united here. Book-value-plus-profitability approaches, earnings-power approaches, peer multiples and the forward-growth projection all land within reach of the quote, and two of the four land above it. Nothing in the set characterises this as a stretch. The approach built specifically for a financial, which starts from tangible book value per share of 70.15 dollars and applies a multiple derived from the return relative to the cost of that capital, lands above the current quote. So does the earnings-based reference that puts a conservative multiple on trailing profit. When every family reaches, the interesting question stops being whether the shares are expensive and becomes why the market is not paying more, which is a question about the durability of the return rather than about its level.

Durability is where the honest hesitation lives. Roughly 60 percent of companies earning a return in this band held it for a decade. That is not a high bar cleared comfortably; it is a coin toss with the odds tilted. And the return has stopped rising: 18.4 percent for the first half of 2026 against 18.8 percent a year earlier on the reported basis, 14.3 percent against 14.4 percent on the operating basis. Flat, not falling, but flat is what the top of a plateau looks like from close up.

Solvency reads differently for an insurer than for an operating company. There is no cash burn to measure and no leverage ratio worth quoting, because policy reserves are the business rather than borrowings against it. What matters is how much of what is earned can leave. Globe Life returns roughly 83 percent of earnings as dividends and repurchases, which means it retains about a sixth. That is the number to hold onto: with a return near the high teens on a sixth of earnings retained, book value compounds in the mid single digits, and the rest of the per-share growth has to come from the share count. It has, falling about 5.6 percent a year over the last four years. The model works. It works because the return persists, and that is the single assumption everything else in this report rests on.

Catalysts

The most recent hard information is three days old. On July 22, 2026, Globe Life reported second-quarter net income of 3.65 dollars a diluted share against 3.05 a year earlier, net operating income of 3.61 against 3.27, and raised full-year 2026 earnings guidance to a range of 15.55 to 15.95 dollars a share, an increase of 10 cents at the midpoint. The company noted that this was the eighth quarter in the last nine with double-digit growth in net operating income per share. A guidance raise of that size is a refinement rather than a reset, and it tells you management sees no surprise in the second half.

The items to watch inside the next few prints are the sales lines rather than the earnings lines. Total life net sales fell 3 percent in the quarter and the direct-to-consumer channel fell 15 percent, while average producing agent count rose 8 percent at Liberty National and 7 percent at Family Heritage. Those two facts have to reconcile eventually: more agents producing fewer sales is a temporary condition, and which way it resolves determines the premium base several years out. Health is the offsetting story, with premium up 16 percent in the quarter and 29 percent at the United American division, though at a lower margin than the life book carries.

On the financing side, Globe Life refinanced its bank facilities in late June 2026, replacing its revolving credit agreement and term loan with amended and restated versions, changing the administrative agent to Wells Fargo and pushing the revolver's maturity from March 2029 out to June 26, 2031. There is nothing dramatic in that; it is housekeeping done from a position of strength, and it removes a refinancing date from the calendar for another two years. The repurchase programme continues underneath it, with 1.1 million shares bought for 175 million dollars in the second quarter alone, drawing on the 1.8 billion dollar authorisation the board approved in November 2024.

Peer Cohorts (Per Segment, With Filing Citations)

Life insurance (reported)

Health insurance (reported)

Investment (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q2 2026 earnings release, July 22, 2026 · company Form 8-K, June 29, 2026

View the full interactive GL report on boothcheck